ITEMS IN AFP WITH KEYWORD:
Breast cancer is the leading cause of death from cancer in women worldwide, and the second most common cause of death from cancer in women in the United States. Risk assessment tools can identify the risk of breast cancer, and patients at high risk may be candidates for risk-reducing medications. Th...
Apr 1, 2021 Issue
Digital Breast Tomosynthesis for Breast Cancer Screening [Diagnostic Tests: What Physicians Need to Know]
There is currently not enough evidence to replace digital mammography with digital breast tomosynthesis for breast cancer screening in women at average or high risk.
The cumulative 20-year follow-up report from the Women's Health Initiative hormone therapy trials found significantly lower breast cancer incidence and mortality among postmenopausal women who previously took conjugated equine estrogen (CEE; Premarin) alone (with a prior hysterectomy) than in women who took a placebo.
Breast cancer is the most common nonskin cancer in women. Numerous risk factors are associated with the development of breast cancer, and a validated risk assessment tool can be used to determine individual risk and guide screening decisions. This article summarizes screening recommendations for average-risk women, as well as the use of supplemental screening in women with risk factors or dense breasts.
Supplemental MRI screening for women with very dense breasts compared with mammography alone every two years significantly reduces the likelihood of an interval cancer, from 5 per 1,000 to 2.5 per 1,000 in the intention-to-treat population and to 0.8 per 1,000 in the per-protocol population.
Mar 15, 2020 Issue
Medication Use to Reduce Risk of Breast Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.
E.F., a 40-year-old woman, comes to your office for a routine gynecologic visit. She is not taking any medications and is generally healthy. She is sexually active, and her last menstrual period started 10 days ago.
It is important that primary care physicians have the ability and resources to identify women eligible for genetic counseling and testing for breast cancer.
Feb 15, 2020 Issue
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool.
Feb 15, 2020 Issue
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer [Putting Prevention into Practice]
A 31-year-old woman presents to your office for a well-woman examination. She is sexually active in a monogamous relationship and has never been pregnant. She tells you that her mother was diagnosed with tubal cancer at age 40 and that her sister, who is 42 years of age, was recently diagnosed with breast cancer.